The NSD2 p.E1099K (EK) mutation is shown to be enriched in patients with relapsed acute lymphoblastic leukemia (ALL), indicating a role in clonal evolution and drug resistance. The gene discussed is NSD2; the disease is acute lymphoblastic leukemia.